April 26, 2017 10:17 AM EDT
News Briefing

An­a­lysts of­fer a luke­warm en­dorse­ment to Am­gen for PhI­II mi­graine da­ta; Ar­sa­nis rais­es $45.5M Se­ries D; Co­v­ance faces re­struc­tur­ing

Shehla Shakoor

Managing Director

→ An­a­lysts took a look at the da­ta on Am­gen’s lat­est Phase III for CGRP mi­graine drug erenum­ab (AMG334) and came away re­as­sured, but …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times